Difference between revisions of "Ruxolitinib (Jakafi)"
m (Text replacement - "http://chemocare.com/chemotherapy" to "https://chemocare.com/chemotherapy") |
|||
| Line 16: | Line 16: | ||
==Patient drug information== | ==Patient drug information== | ||
*Patient information may be found in the [https://www.jakafi.com/pdf/prescribing-information.pdf Ruxolitinib (Jakafi) package insert]<ref name="insert"></ref> | *Patient information may be found in the [https://www.jakafi.com/pdf/prescribing-information.pdf Ruxolitinib (Jakafi) package insert]<ref name="insert"></ref> | ||
| − | * [ | + | * [https://chemocare.com/chemotherapy/drug-info/ruxolitinib.aspx Ruxolitinib (Jakafi) patient drug information (Chemocare)]<ref>[https://chemocare.com/chemotherapy/drug-info/ruxolitinib.aspx Ruxolitinib (Jakafi) patient drug information (Chemocare)]</ref> |
* [http://www.uptodate.com/contents/ruxolitinib-patient-drug-information Ruxolitinib (Jakafi) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ruxolitinib-patient-drug-information Ruxolitinib (Jakafi) patient drug information (UpToDate)]</ref> | * [http://www.uptodate.com/contents/ruxolitinib-patient-drug-information Ruxolitinib (Jakafi) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ruxolitinib-patient-drug-information Ruxolitinib (Jakafi) patient drug information (UpToDate)]</ref> | ||
Revision as of 21:43, 16 December 2021
General information
Class/mechanism: Kinase inhibitor of Janus Associated Kinases (JAKs) JAK1 and JAK2. Modulates gene expression by interfering with the JAK signaling pathway, which involves recruitment, activation, and localization of STATs (signal transducers and activators of transcription) to cytokine receptors and the nucleus.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1][3]
Diseases for which it is used
- Acute myeloid leukemia
- Chronic lymphocytic leukemia
- Graft versus host disease
- Hypereosinophilic syndrome
- Myelofibrosis
- Polycythemia vera
Patient drug information
- Patient information may be found in the Ruxolitinib (Jakafi) package insert[1]
- Ruxolitinib (Jakafi) patient drug information (Chemocare)[4]
- Ruxolitinib (Jakafi) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 11/16/2011: Initial FDA approval for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. (Based on COMFORT-I and COMFORT-II)
- 12/4/2014: Indication expanded for the treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea (HU). (New disease entity; based on RESPONSE)
- 5/24/2019: Indication expanded for steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older. (New condition; based on REACH1)
- 9/21/2021: Approved for chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. (Based on REACH3)
Also known as
- Code name: INCB018424
- Generic name: ruxolitinib phosphate
- Brand names: Jakafi, Jakavi